Covered recipient · General Payments record
MALIKA GILL
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
General Payments · PY2025
$254.75
- Reported across 10 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $174.76 | 9 |
| Education | $79.99 | 1 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $130.06 | 4 |
| Merck Sharp & Dohme Corporation | $63.52 | 3 |
| AIMMUNE THERAPEUTICS, INC. | $23.48 | 1 |
| Napo Pharmaceuticals Inc | $20.01 | 1 |
| Gilead Sciences, Inc. | $17.68 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2025 | $254.75 | 10 |
Payment records · PY2025 (10)
Ordering applied by this site (paying entity, then date) · record values are shown as CMS published them
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | $23.48 | 10/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249660351 | CMS |
| Astellas Pharma US Inc | $21.74 | 10/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238688881 | CMS |
| Astellas Pharma US Inc | $13.48 | 11/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238583634 | CMS |
| Astellas Pharma US Inc | $79.99 | 12/03/2025 | Education | Undisputed | 06/30/2026 | 1238591716 | CMS |
| Astellas Pharma US Inc | $14.85 | 12/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238620266 | CMS |
| Gilead Sciences, Inc. | $17.68 | 11/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234551885 | CMS |
| Merck Sharp & Dohme LLC | $22.27 | 10/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238077279 | CMS |
| Merck Sharp & Dohme LLC | $14.38 | 11/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238011756 | CMS |
| Merck Sharp & Dohme LLC | $26.87 | 12/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238163476 | CMS |
| Napo Pharmaceuticals Inc | $20.01 | 12/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1223619608 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2025
- Source files
- Dataset page · Bulk file · PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.